XML 20 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 65,813,297 $ 14,310,862
Short-term investments 28,300,232 130,982,913
Accounts receivable 1,199,056 2,405,228
Prepaid expenses and other current assets, including with affiliated entity 2,517,465 5,414,097
Total current assets 97,830,050 153,113,100
Fixed assets, net 3,659,818 4,960,986
Investments in affiliated entity 1,613,844 2,780,287
Operating lease right-of-use assets 8,113,840 9,491,735
Other assets 1,979,654 605,315
Total assets 113,197,206 170,951,423
Current liabilities:    
Accrued clinical trial expenses 2,021,860 2,365,382
Common stock warrant liability 13,255,188 0
Operating lease liability 2,497,360 2,406,522
Grant funding liability, including from affiliated entity 0 109,407
Convertible senior notes 0 16,770,654
Total current liabilities 35,325,584 42,570,228
Operating lease liability, net of current portion 9,367,827 11,032,066
Total liabilities 44,693,411 53,602,294
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December 31, 2024 and 2023 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2024 and 2023, issued and outstanding: 36,099,991 at December 31, 2024 and 22,793,075 at December 31, 2023 36,099 22,792
Additional paid-in capital 1,799,362,625 1,740,954,074
Accumulated deficit (1,730,219,262) (1,622,965,136)
Accumulated other comprehensive loss (675,667) (662,601)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 68,503,795 117,349,129
Total liabilities and stockholders’ equity 113,197,206 170,951,423
Nonrelated Party    
Current liabilities:    
Accounts payable and accrued expenses 16,200,013 19,847,744
Related Party    
Current liabilities:    
Accounts payable and accrued expenses $ 1,351,163 $ 1,070,519